Cash and cash equivalents were $10.3M as of December 31, 2025, compared with $16M as of December 31, 2024. With these funds and proceeds from the January 2026 public offering, the company expects its cash position will be adequate to fund operations into the fourth quarter of 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MTVA:
- Metavia Inc. (MTVA) Q4 Earnings Cheat Sheet
- MetaVia Advances DA-1726 Obesity Drug into Phase 1 Part 3
- MetaVia announces IRB at Clinical Pharmacology of Miami approved Phase 1 study
- MetaVia expands global patent protection for vanoglipel into 2035
- Vanguard Total Stock Market ETF (VTI) Daily Snapshot—3/11/26